The collaboration spans custody, asset management, lending, trading, and capital markets, enabling Elevation Point to deliver differentiated solutions tailored to the complex needs of elite partner teams and their sophisticated clients. MINNEAPOLIS, Sept. 2, 2025 /PRNewswire/ -- Elevation Point, a growth accelerator and minority stake partner for independent advisors, today announced a strategic collaboration with Goldman Sachs to offer its partner firms access to Goldman Sachs' banking and lending, trading ...

MACAU, Aug. 25, 2025 /PRNewswire/ -- EPSIUM Enterprise Limited (NASDAQ: EPSM) ("EPSIUM" or the "Company"), a Nasdaq-listed holding company, today announced that it has entered into a non-binding Memorandum of Understanding ("MOU") with Era Future (Macau) Performance Art Limited ("Era Future"), a Macau SAR-based company specializing in variety show planning, event operations, film and television production support, and integrated marketing.The MOU outlines the parties' intention to engage in good faith discu ...

Core Insights - Lightera and Optical Cable Corporation (OCC) have entered into a strategic collaboration agreement aimed at expanding product offerings and solutions for the data center and enterprise sectors [1][3] - Lightera has made an investment in OCC, acquiring 7.24% of the company's outstanding shares [4] Company Information - Lightera is recognized as a global leader in optical fiber and connectivity solutions, known for its innovative technologies and high-performance optical fibers [2][6] - OCC is a leading manufacturer of fiber optic and copper cabling solutions, with a strong reputation for innovative technologies and product designs [2][8] - Both companies have a long-standing relationship, having partnered in various capacities over the years, which has now culminated in this strategic collaboration [2][3] Strategic Collaboration Benefits - The collaboration is expected to enhance both companies' ability to offer integrated cabling and connectivity solutions, particularly in the enterprise and data center sectors [3][5] - The partnership aims to leverage the combined product portfolios of OCC and Lightera to meet the growing demands of critical customer segments [3][5] - Management from both companies expressed confidence that this collaboration will accelerate sales growth and create significant value for shareholders [5]

Core Insights - Virtu Financial and Limina have announced a strategic collaboration to enhance Virtu's TradeOPS platform, aimed at improving post-trade workflows for buyside firms [1][2]. Group 1: Collaboration Details - The collaboration focuses on integrating Virtu's TradeOPS with Limina's cloud-native Order and Portfolio Management System (O/PMS), providing a fully-integrated workflow for clients [2]. - The first joint client, Cliens, is already utilizing the combined capabilities of Virtu's TradeOPS and Limina's platform [3]. - The partnership aims to address operational challenges introduced by recent changes in post-trade settlement processes, such as the shift to T+1 [4]. Group 2: Company Profiles - Virtu Financial is a leading financial services firm that offers execution services, data analytics, and connectivity products across multiple asset classes and global markets [6]. - Limina provides a modern Investment Management Platform designed to enhance productivity and manage operational risks for investment managers [7]. - Cliens is a Swedish active fund manager focused on delivering long-term high returns through various investment strategies [8].

Group 1 - Pfizer Inc. is set to release its Q1 earnings results on April 29, with expected earnings of 68 cents per share, a decrease from 82 cents per share in the same period last year [1] - The projected quarterly revenue for Pfizer is $14.09 billion, down from $14.88 billion a year earlier [1] - Guardant Health announced a strategic collaboration with Pfizer to enhance the development and commercialization of Pfizer's oncology portfolio using the Guardant Infinity smart liquid biopsy platform [2] Group 2 - UBS analyst Trung Huynh maintained a Neutral rating on Pfizer and reduced the price target from $28 to $24 [7] - Goldman Sachs analyst Asad Haider downgraded Pfizer from Buy to Neutral, cutting the price target from $32 to $25 [7] - Guggenheim analyst Vamil Divan reiterated a Buy rating for Pfizer, indicating a positive outlook [7]